Strong U.S. demand eases pressure on Novo to show weight-loss drug’s health benefits
By Maggie Fick LONDON (Reuters) – Soaring U.S. demand for Novo Nordisk’s weight-loss drug has reduced the pressure from investors on the company to deliver strong results in its trial to test whether the drug also has medical benefits, eight investors and analysts say. Novo is expected to publish in August the results of a…
